Number of pages: 53
Posted: 10 Jul 2018
Ji Zhang,
Eric S. Muise,
Peter S. Kutchukian,
Philippe Costet,
Yonghua Zhu,
Yanqing Kan,
Haihong Zhou,
Vinit Shah,
Yongcheng Huang,
Taro E. Akiyama,
Xiao-Lan Shen,
Tian-Quan Cai,
Kashmira Shah,
Emanuel Zycband,
Lan Yi,
Ye Tian,
Ying Chen,
Jason Imbriglio,
Elizabeth Smith,
Kristine Devito,
James Conway,
Li-Jun Ma,
Maarten Hoek, Andrea M. Peier,
David G. McLaren,
Stephen F. Previs and
Shirly Pinto
Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Genetics and Pharmacogenomic (GpGx), Merck & Co., Inc. - Department of Chemistry, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Safety Assessment and Laboratory Animals Resources (SALAR), Merck & Co., Inc. - Department of Pharmacology, Merck & Co., Inc. - Department of Pharmacology, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM), Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Chemistry, Merck & Co., Inc. - Department of Pharmacology, Merck & Co., Inc. - Department of Pharmacology, Merck & Co., Inc. - Department of Genetics and Pharmacogenomic (GpGx), Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Cardiometabolic Diseases, Merck & Co., Inc. - Department of Pharmacology, Merck & Co., Inc. - Department of Chemistry, Merck & Co., Inc. - Department of Cardiometabolic Diseases and Merck & Co., Inc. - Department of Cardiometabolic Diseases